Yilian Litong Completes Seed Funding Round, Domestic Second-Gen Prostatic Urethral Lift System 'Kunpeng' Leads the Minimally Invasive BPH Treatment Market

VCBeat has exclusively learned that,Hefei MEDLINK Medical Technology Co., Ltd. (hereinafter referred to as “MEDLINK”)Recently completed seed round financing, led byHefei Industrial Investment Guozheng InvestmentandHefei Baohe Venture CapitalJoint Investment,YCAPITALServing as long-term financial advisor. The proceeds from this financing round will be used to accelerate mass production validation, clinical studies, and the R&D and upgrading of the third-generation product for the company’s core product, the “Kunpeng” Generation II Suspension System, further consolidating its leading position in the field of minimally invasive treatment for benign prostatic hyperplasia (BPH).

Benign prostatic hyperplasia (BPH) is one of the most prevalent conditions in urology. In China, the prevalence among men aged 50 and above exceeds 50%, with an increasing incidence observed in younger populations year by year. Traditional treatments, such as pharmacotherapy and transurethral resection, are associated with high risks of complications and sexual dysfunction. Although imported suspension devices enable ultra-minimally invasive therapy, they remain costly and have not yet been domestically produced in China.

MEDLINK’s independently developed “Kunpeng” Suspension System, as the first domestically produced second-generation product of its kind, has overcome the technical bottleneck limiting efficacy across a wide range of gland volumes. It resolves the issues associated with first-generation suspension products, namely insufficient restraining force for small glands and inadequate stabilization for large glands. Its modular design enables more stable quality control, reduces the frequency of endoscope assembly and disassembly, and significantly enhances puncture stability.

Compared with imported products, the “Kunpeng” system offers simpler operation and higher stability, thereby reducing the likelihood of clinical operational errors. This product does not require complex equipment support, enabling its deployment in township hospitals and significantly improving treatment accessibility.

“Kunpeng” adopts an innovative split-type structure, surpassing international counterparts in terms of safety, efficacy, and cost control. Its core advantages include:

• Technological Leadership:As the second suspension system worldwide and the first domestically produced one to effectively address the limitations imposed by large gland volumes, its performance benchmarks against the most advanced international standards;

• Clinically Friendly: The procedure is short in duration, with significant immediate postoperative efficacy; it preserves 100% of patients’ sexual function, and hospitalization requirements can be reduced to an outpatient level;

• Inclusive Healthcare:The treatment cost is comparable to that of traditional transurethral resection, and it is expected to be included in the national medical insurance coverage within the next 3–5 years, further reducing the financial burden on patients.

Currently, “Kunpeng” has entered the mass production stage for prototypes, with a planned market launch in 2027. Meanwhile, the company is accelerating the R&D of its third-generation upgraded product, expecting to release a prototype in the fall of 2025, thereby continuing to lead technological iteration.

MEDLINK's Self-Developed "Kunpeng" Suspension System

Hefei Industrial Investment Guozheng InvestmentHe stated, “There are indeed numerous treatment modalities for benign prostatic hyperplasia (BPH), and we have conducted comprehensive research. Overall, the trend toward minimally invasive surgical approaches remains constant. Treatment preferences vary depending on patient age and disease severity, indicating that there are still significant gaps to be filled in this sector. Given the large and rapidly growing base of BPH patients, high-quality minimally invasive products are poised to excel in this field.”

Hefei Baohe Venture Capital“We believe that Mr. Cao has accumulated extensive expertise in the medical device sector, and we strongly concur with his insights into the industry. Population aging is a clear trend, and Chinese-made medical devices now require greater innovation, breakthroughs, and professionalized management during industrialization. The suspension therapy products developed by MEDLINK demonstrate their competitiveness across multiple dimensions. Currently, Baohe District in Hefei places significant emphasis on outstanding innovative products in the life and health sector. We hope to collaborate with more exceptional medical entrepreneurs to jointly build a superior medical industry platform, benefiting patients both domestically and internationally.”

Cao Jie, Founder and CEO of MEDLINKstated: “Our elders have gradually reached the age where they are susceptible to benign prostatic hyperplasia (BPH). They have made tremendous sacrifices and contributions to the nation, their workplaces, and their families. Conventional treatment modalities present numerous pain points. We aim to develop domestically produced medical devices that are more minimally invasive and offer superior performance, thereby providing them with a wider range of better options.”

Project Lead, YCAPITALstated, “It is a great honor to serve as the long-term financial advisor for MEDLINK’s current round of financing. BPH suspension procedures hold a considerable market share overseas, while the domestic market in China remains largely untapped. With overseas giants updating their product lines, second-generation products are poised to become mainstream in the future. MEDLINK is well-positioned to achieve import substitution and upgrading through its product portfolio, emerging as a domestic leader in urology.”

As mass production of the “Kunpeng” system approaches, MEDLINK is poised to break the import monopoly and drive the upgrade of BPH treatment toward ultra-minimally invasive, outpatient-based care, providing a new model for the breakthrough of high-end domestic medical devices.The company is about to launch a new round of financing, with YCAPITAL continuing to serve as its long-term financial advisor.